Skip to content

A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508280-69-00
Acronym
CA111-001
Enrollment
27
Registered
2024-01-09
Start date
2022-10-07
Completion date
2024-08-16
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Malignant Tumors

Interventions

None listed

Sponsors

Bristol Myers Squibb International Corporation, Bristol Myers Squibb International Corporation
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026